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ABSTRACT 
Background 
Recent studies have discovered that -globin is expressed in blood vessel 
walls where it plays a role in regulating vascular tone. We tested the 
hypothesis that blood pressure might differ between normal individuals and 
those with +thalassemia, in whom the production of -globin is reduced.  
Methods and Results 
The study was conducted in Nairobi, Kenya, among 938 adolescents aged 
11-17 years. 24-hour ambulatory blood pressure monitoring (ABPM) and 
arterial stiffness measurements were performed using an arteriograph device. 
We genotyped for +thalassemia by PCR. Complete data for analysis were 
available for 623 subjects; 223 (36%) were heterozygous (-α/αα) and 47 (8%) 
were homozygous (-α/-α) for +thalassemia while the remaining 353 (55%) 
subjects were normal (αα/αα). Mean 24-hour systolic BP±SD was 118±12 
mmHg in αα/αα, 117±11 mmHg in -α/αα and 118±11 mmHg in -α/-α subjects 
respectively. Mean 24-hour diastolic BP ±SD in these groups was 64±8 
mmHg, 63±7 mmHg and 65±8 mmHg respectively. Mean pulse wave velocity 
(PWV)±SD was 7±0.8 ms-1, 7±0.8 ms-1 and 7±0.7 ms-1 respectively. No 
differences were observed in PWV and any of the 24-hour ABPM derived 
measures between those with and without +thalassemia.  
Conclusion 
These data suggest that the presence of +thalassemia does not affect blood 
pressure and/or arterial stiffness in Kenyan adolescents. 
Keywords 
+thalassemia, ambulatory blood pressure monitoring, adolescents
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INTRODUCTION 
The thalassemias, in which there is disordered or absent production of the - 
or -globin chains that make up normal hemoglobin, are the most common 
monogenic disorders of humans.1 The geographical distribution of 
+thalassemia, in which there is deletion of one or more of the HBA genes 
that encode -globin (Hb) production, closely mirrors that of malaria 
transmission2 and it has been demonstrated that these deletions confer 
protection against both severe and non-severe malaria.2-5 
While it has long been believed that Hb expression is limited to red blood 
cells, it has recently been demonstrated that Hb is also expressed in mouse 
endothelial cells where it plays a role in nitric oxide (NO) signaling, influencing 
vascular smooth muscle tone in resistance arteries.6, 7 A macromolecular 
complex formed by Hb and endothelial Nitric Oxide Synthase (eNOS), 
regulates NO signaling at myoendothelial junctions (MEJ).8 Disruption of this 
complex lowers BP in both normotensive and hypertensive mice.8 It has also 
been shown that resistance arteries from mice lacking 2 of the 4 globin 
genes (- have reduced contractility after treatment with the 
vasoconstrictor phenylephrine.9 Individuals with +thalassemia have been 
shown to have higher microvasculature tortuosity.10 From the foregoing it 
could be expected that individuals with +thalassemia might have lower BP 
compared to those with normal hemoglobin. However the few studies 
conducted in humans have yielded inconsistent results. While one review11 
suggested that +thalassemic individuals have moderate hypotension, other 
investigators have found elevated BPs in subjects with this condition.12, 13 
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These studies were limited by small sample sizes and the failure to use 24-
hour ambulatory blood pressure monitoring (ABPM) to measure BP. It is 
known that one-off office/clinic BP measurements can be influenced by a 
variety of environmental and psychological factors14, limitations that are 
overcome by the use of ABPM, which is considered the reference standard 
for BP measurement.14, 15  
If arterial stiffness and/or BP are influenced by Hbα genotype, this would an 
important step that could aid the development of compounds either mimicking 
or antagonizing Hbα as potential therapies for hypertension. In the current 
study, we have tested the hypothesis that 24-hour BP and arterial stiffness is 
different in subjects with +thalassemia than in normal individuals.  
METHODS 
This population-based study was a cross-sectional sample of residents of the 
Nairobi Urban Health and Demographic Surveillance System (NUHDSS)16 in 
Kenya, and was conducted between December 2015 and June 2016. Nairobi, 
the capital city of Kenya was chosen for this study for 2 reasons. First, Nairobi 
is located at high altitude (1800 meters above sea-level) and there is no 
evidence of malaria transmission.17 This made it possible to study the effect of 
+thalassemia on BP unconfounded by the presence of malaria, which could 
potentially influence BP18 and which +thalassemia protects against. Second, 
the population of Nairobi is composed of ethnic groups originating from all 
parts of the country including those whose ancestral lands were endemic for 
malaria (e.g. Luhya, Luo, Teso, Mijikenda), in whom the frequency of 
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+thalassemia is significantly higher.2 In order to increase our efficiency in 
recruiting participants with +thalassemia, we limited our recruitment to those 
who identified themselves as genetically derived from one of these ethnic 
groups.  
The NUHDSS conducts population-wide censuses within the study area 4 
times each year.16 Using NUHDSS data we selected all children currently 
aged 11-17 years who had a continuous record of residence within the study 
area since birth. Continuous residency was a requirement in order to minimize 
potential exposure to malaria as a result of migration. Trained staff visited all 
subjects who had been selected to participate in the study at their homes. 
Parents of the children were then asked to bring them to the nearer of two 
study clinics within the area to undergo study procedures. Up to three 
attempts were made at finding a selected subject before concluding that they 
could not be found. Subjects who failed to come to the clinic within 3 months 
of being invited were considered to have declined to participate in the study.  
Recruited subjects first underwent an interview where they answered 
questions about their past medical history and their socioeconomic status 
based on the multi-dimensional poverty (MDP) index.19 Weight and height 
were measured using a validated SECA 874™ weighing machine and a 
portable stadiometer (SECA 213™), respectively. Mid-upper-arm 
circumference (MUAC) was measured in a standardized manner using 
TALC™ MUAC tapes. We then took a screening BP measurement using a 
validated Omron™ M10-IT sphygmomanometer. An appropriately sized cuff 
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was placed on the non-dominant arm after the subject had been seated for at 
least 5 minutes. Three BP measurements were taken over a 5-minute period 
and the mean of the last 2 measurements was recorded as the screening BP 
value. All participants were subsequently fitted with a validated 
Arteriograph24™ device for 24-hour ABPM as well as pulse wave velocity 
(PWV) determination.20 These devices were programmed to take 
measurements every 20 minutes from 0600-2200 hrs and every 40 minutes 
from 2200-0600 hrs. 
 As there are no published criteria for acceptable ABPM data in children, we 
used guidelines for completeness of ABPM data in adults from the 
International Database of Ambulatory blood pressure in relation to 
Cardiovascular Outcomes (IDACO) study.21 Specifically, ABPM data were 
considered of acceptable quality if they included a minimum 10 daytime and 
minimum 5 nighttime readings, where daytime was defined as 1000-2200 hrs 
and nighttime as 0000-0600 hrs.21 The same time periods were used to 
determine average daytime and nighttime blood pressures and to evaluate 
dipping status. Time weighting was applied in calculating average BP values 
for all time periods.22  
We defined screen positives for hypertension as individuals whose mean of 
the last 2 clinic BP measurements was above the 95th percentile for their age, 
sex and height.15 Confirmed hypertensives were those whose 24hr systolic 
and/or diastolic BP averages respectively were above the 95th percentile for 
their sex, age and height.15  
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We categorized all subjects who were not on anti-hypertensive medication 
using the combination of clinic BP measurements and ABPM into four 
categories: sustained hypertensives (screen positive and confirmed 
hypertensive on ABPM); white coat hypertensives (screen positive, not 
confirmed hypertensive on ABPM); masked hypertensives (screen negative, 
confirmed hypertensive on ABPM) or normotensives (screen negative, not 
confirmed hypertensive on ABPM).23  
Dipping status was defined using ABPM data only, using day and night 
periods as defined above. Subjects were classified using the following four 
categories, based on the night/day ratio of mean systolic and/or diastolic BPs: 
rising or absence of dipping (ratio ≥1.0); mild dipping (0.9 < ratio ≤1.0); 
dipping (0.8 < ratio ≤ 0.9); and extreme dipping (ratio≤0.8).24 
Laboratory procedures 
We collected 10ml of blood from participants for full blood count, 
determination of +thalassemia genotype and serum electrolytes. After 
performing automated full blood counts using an ACT 5™ machine, whole 
blood samples were frozen at -80ºC and then transported to the KEMRI-
Wellcome Trust Research Programme laboratories in Kilifi, Kenya for 
genotyping. DNA was extracted retrospectively from the frozen samples by 
use of Qiagen™ DNA blood mini-kits (Qiagen, Crawley, United Kingdom) and 
typed for the common African -3.7kb HBA deletion by PCR.25 
Serum and urine samples collected from participants were frozen at -80ºC 
within 4 hours of collection and later transported to Kilifi, Kenya for 
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subsequent analysis. We determined sodium and potassium, urea and 
creatinine levels in these samples using ion electrophoresis and the Jaffe 
method, respectively.26 We additionally determined albumin levels in the urine 
samples by immunoturbidometry using a Quantex™ microalbumin kit. 
Estimated glomerular filtration rate (eGFR) was calculated using the Schwarz 
formula.27 
Statistical methods 
Based on an expected minimum prevalence for heterozygous +thalassemia 
(-α/αα) of 20% in the ethnic groups we were studying, a systolic BP standard 
deviation of 15 mmHg, and 30% attrition due to poor quality ABPM data, we 
estimated that a total of 472 participants would provide 80% power to detect 
1/3rd of a standard deviation (5 mmHg) difference in 24 hour systolic BP 
between -α/αα and αα/αα individuals.  
Summary statistics that were computed included means, medians and 
proportions as appropriate. We used Student’s t-test to separately compare 
continuous variables in –α/αα  and –α/–α  to αα/αα individuals. The 2 test 
was used to compare categorical variables. We conducted multiple regression 
analyses to determine whether inclusion of α+thalassemia genotype predicted 
24-hour systolic and/or diastolic BP. Age, sex, BMI, eGFR, and PWV, which 
have all been previously associated with BP were included as covariates in 
the base model. To determine whether α+thalassemia genotype influenced 
24-hour BP, we added it to the base model and used the likelihood ratio test 
to determine if it improved the fit. We additionally tested for interaction with 
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the sickle cell trait, as it has previously been associated with cardiovascular 
and renal events28-31. All analyses were conducted using Stata™ Version 12 
software (College Station, Texas). 
The Kenya Medical Research Institute’s Ethical Review Committee approved 
the study. Written informed consent was obtained from parents of study 
participants. Participating children also provided written assent.  
RESULTS 
Of the 938 subjects invited to participate in the study, 686 completed 
enrollment (Figure 1). None of the participants were previously aware of their 
α+thalassemia status. The 252 adolescents that were not recruited into the 
study were 0.6 years (95% CI 0.3-0.9) older than study participants, but with a 
similar sex distribution (53% female) to those that participated in the study. 
Data on α+thalassemia genotype were available for 664 (97%) participants. 
246 (37%) were heterozygous (-α/αα) and 49 (7%) were homozygous (-α/-α) 
for +thalassemia while the remaining 369 (56%) of subjects were normal 
(αα/αα). One hundred and three (15.5%) of the adolescents were carriers of 
the sickle cell trait, distributed equally among the +thalassemia genotypic 
groups (14%, 17% and 16% in αα/αα, -α/αα and -α/-α subjects respectively, 
p=0.652). After excluding those with poor quality ABPM data, 623 (94%) 
subjects provided quality data for the analysis (Figure 1). A slightly lower 
proportion of -α/αα participants had complete ABPM data (91%) compared to 
αα/αα (95%) and -α/-α subjects (97%). Mean clinic BP±SD among all 
participants was 98±11 mmHg systolic and 64±8 mmHg diastolic. The mean 
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24-hour BP±SD for all participants was 117±12 mmHg systolic and 64±8 
mmHg diastolic. Mean 24-hour Pulse Wave Velocity (PWV)±SD was 7±0.8 
ms-1. The study had >98% power to detect 1/3rd of a standard deviation (SD) 
difference in either systolic or diastolic BP (4mmHg and 2.7mmHg 
respectively) between αα/αα individuals and those with -α/αα, and a 0.3 ms-1 
(1/3rd SD) difference in PWV between αα/αα individuals and those with -α/αα. 
The study had >90% power to detect differences equivalent to 0.5 SDs in BP 
and PWV between αα/αα and  -α/-α individuals. 
Table 1 displays the characteristics of study participants according to 
+thalassemia genotype. As expected, hemoglobin concentrations were 
significantly lower in -α/-α than in -α/αα or αα/αα subjects. BMI was lower in   -
α/αα than in αα/αα individuals (18.2 vs 19.2;  p=0.0004) while mid upper arm 
circumference was significantly smaller in -α/αα compared to αα/αα 
individuals. There were no statistically significant differences in the 
prevalence of masked hypertension, white coat hypertension or in the pattern 
of non-dipping BP by +thalassemia genotype. PWV was also similar in all 3 
groups. 
Figure 2 displays mean 24-hour, daytime and nighttime blood pressures in 
study participants by +thalassemia genotype. All measures were similar for 
all three groups.  
The results of regression analyses are displayed in Table 2. Age, sex, BMI, 
eGFR and PWV were all independent predictors of 24-hour systolic BP while 
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PWV was the only independent predictor of 24-hour diastolic BP. 24-hour BP 
values were not associated with +thalassemia genotype in any of our 
regression models and its inclusion in the final model did not improve the fit 
(likelihood ratio test p=0.96 for systolic BP and p=0.75 for diastolic BP). 
Adjustment for proxy markers of hemolysis (hemoglobin level, mean 
corpuscular volume and mean corpuscular hemoglobin concentration) made 
no difference to the results, and neither did the inclusion of interaction terms 
for sex and sickle cell trait status. 
DISCUSSION 
The +thalassemias are the most common human monogenic disorders1. 
Demonstration of altered BP in individuals with any of the mutations would be 
of immense importance, as it would improve the understanding of BP 
regulation and aid the development of new drugs. In this detailed study of BP 
phenotypes and arterial stiffness among adolescents, we did not find any 
differences between those with and without +thalassemia. Because the 
exposure measurement was a genetic trait acquired at conception and the 
participants were ascertained to have remained in the same malaria-free 
environment since birth we believe that this study suggests that a direct effect 
of +thalassemia on BP and indices of arterial stiffness within the first 11-17 
years of life is highly improbable. 
On the face of it, our results do not align with findings from other studies that 
have suggested the possibility that expression of Hbα might affect blood 
pressure.6, 8, 11 These studies were either done in-vitro or in mouse models 
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with very limited sample sizes (N=6).8 The review by Butcher et al11 that 
reported an association between +thalassemia and moderate hypotension 
did not refer to a primary publication. It is possible that the lower BPs 
observed in subjects with +thalassemia who are relatively protected from 
malaria could actually be a confirmation that malaria raises blood pressure as 
we have previously hypothesized.18 An alternative explanation for similar BP 
despite the presence of Hbα deletions could be due to canalization, a 
phenomenon where individuals or organisms develop the same phenotype 
despite differences in their genetic make up.32 Reddy et al33 have shown that 
infusion of HbH (levels of which are elevated in +thalassemia) into rats 
results in elevation of BP as a result of HbH having higher affinity for Nitric 
Oxide than HbA.34 It is therefore possible that the BP lowering effect of 
+thalassemia is cancelled out by the opposing effect of elevated levels of 
HbH. This would also suggest that recently developed molecules that mimic 
alpha globin35, may have reduced effectiveness in individuals with 
+thalassemia. Additional studies are needed to fully understand these 
seemingly contrasting effects and generate a unified model incorporating both 
environmental conditions and genetic effects. 
A major strength of this study was the use of ABPM, which is considered the 
reference standard for blood pressure measurement in children.15 The study 
was well powered to detect very small differences in BP and PWV. Although it 
could be argued that PWV is predominantly a measure of large conduit 
arteries which do not express Hb alpha  integrates the 
interface between small arteries and resistance vessels-as for instance in 
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diabetes where small vessel damage is as frequent as large.36 An additional 
strength of the study is that we used health and demographic surveillance 
system (HDSS) records that were prospectively collected in order to ascertain 
residence in a non-malaria zone, there being no better method of doing this in 
sub-Saharan Africa. 
One limitation of this study was the limited age range of subjects recruited, 
necessitated by the fact that there were no long-term residency records for 
older individuals. Most HDSSs in sSA were established in the late 1990’s to 
early 2000’s.37 Recruiting older individuals would have compromised data on 
residency status in childhood, the period when malaria risk is highest. While 
BP differences are likely to be larger at older ages, it is known that differences 
in adult BP emerge in childhood38, 39 and that childhood BP levels are 
predictive of adult BP.40 The absence of even a small difference in carefully 
measured BP and arterial stiffness in our study of adolescents therefore 
suggests that it is very unlikely such differences would emerge in future. 
A second limitation of the study is the fact that we did not measure levels of 
markers of hemolysis such as HbH and haptoglobin and other potential 
compensatory mechanisms such as (decreased) eNOS or guanylyl cyclase 
expression, or increased catecholamine levels among study participants. This 
would have helped to either confirm or refute the possibility of canalization 
explaining the lack of an effect of +thalassemia on BP levels. This could form 
the basis of future studies to better understand the seemingly contrasting 
findings of experimental and human studies. 
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It is also important to note that no studies have to date established whether 
alpha hemoglobin is expressed in endothelial cells of human subjects and if 
the 3.7kb deletion, the most common defect causing + thalassemia1 in 
humans, also results in reduced endothelial expression of alpha hemoglobin. 
Additional studies are required to determine if there is endothelial expression 
of alpha hemoglobin in humans, whether the 3.7kb deletion results in reduced 
endothelial  globin expression and whether other defects resulting in 
thalassemia present with the same vascular phenotype that we observed. 
In summary, we have demonstrated that there are no differences in BP and 
arterial stiffness based on +thalassemia genotype in Kenyan adolescents 
living within a non-malaria-endemic environment. Additional studies are 
required to explain the apparent contradictory results of experimental studies. 
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Table 1: Characteristics of study participants (N=623) 
 
Characteristic Normal 
(αα/αα) 
N=353 
Heterozy
gous 
(-α/αα) 
N=223 
Homo
zygou
s 
(-α/-α) 
N=47 
p-
value1 
p-
value2 
Age, years 
13.4 
(2.2) 
13.0 
(2.2) 
13.4 
(2.4) 0.0289 0.9 
Female, No. (%) 
187 
(53) 
132 
(59) 
28 
(58) 0.3 0.3 
BMI1, kg/m2 
19.2 
(3.2) 
18.3 
(2.6) 
19.2 
(3.6) 0.0004 0.9 
MUAC2, cm 
23.7 
(3.9) 
22.7 
(3.1) 
23.2 
(4) 0.0007 0.4 
Hemoglobin, mg/dL 
13.5 
(1.5) 
13.1 
(1.4) 
12.2 
(1.6) 0.0004 <0.0001 
Mean cell volume (fL) 
84 
(5) 
79 
(5) 
70 
(5) <0.0001 <0.0001 
Mean corpuscular hemoglobin 
concentration (g/dL) 
32 
(2) 
31 
(2) 
31 
(2) 0.0003 <0.0001 
Socioeconomic status (MDPI3 
score) 
2.0 
(1.2) 
2.3 
(1.4) 
2.4 
(1.1) 0.0126 0.3 
24-hour SBP (mmHg) 
118 
(12) 
117 
(11) 
118 
(11) 0.1 1.0 
24-hour DBP (mmHg) 
64 
(8) 
63 
(7) 
65 
(8) 0.1 0.6 
24-hour Pulse wave velocity 
(ms-1) 
7.0 
(0.8) 
7.0 
(0.8) 
7.0 
(0.7) 0.2 0.5 
Systolic Morning BP surge, 
mmHg 
 
9 
(12) 
8 
(12) 
11 
(10) 0. 6 0.2 
Augmentation index, % 
17 
(6) 
17 
(6) 
16 
(5) 0.8 0.4 
White coat hypertension, No 
(%) 
15 
(4) 
8 
(4) 
3 
(6) 0.2 0.4 
Masked hypertension, No (%) 
25 
(7) 
21 
(9) 
7 
(15) 1.0 0.073 
Non dipping BP pattern 
24 
(7) 
7 
(3) 
2 
(4) 0.1 0.9 
eGFR4  (mls/min/1.73m2) 
109 
(15) 
111 
(14) 
110 
(13) 0.1 0.6 
Log10UACr  
0.4 
(0.6) 
0.3 
(0.7) 
0.2 
(1) 0.4 0.1 
Urine sodium (mmol/L) 
137 
(82) 
130 
(53) 
128 
(51) 0.3 0.5 
Urine potassium (mmol/L) 
48 
(32) 
46 
(29) 
42 
(20) 0.4 0.2 
Data are mean (SD) unless specified 
P-values are for comparisons between normal and heterozygous1 and normal and homozygous2 
1BMI=Body mass index 
2MUAC=mid upper arm circumference 
3MDPI=multi-dimensional poverty index 
4eGFR=estimated glomerular filtration rate 
 
 
 
 21 
 
 
 
 
 
Table 2: Regression analyses investigating possible effect of thalassemia 
status on 24-hour systolic and diastolic BP 
 
 
 
24hr SBP 24 hr- DBP 
, 95% CI p-value , 95% CI p-value 
Age (years) 0.6 (0.1 to 1.2) 0.021 0.03(-0.3 to 0.4) 0.9 
Male sex 2.6(0.7 to 4.5) 0.009 0.2(-1.1 to 1.4) 0.9 
BMI (kg/m2) 0.6 (0.2 to 1) 0.001 0.2(-0.1 to 0.4) 0.2 
PWV (ms-1) 2.8(1.6 to 4.1) <0.001 2.7(1.9 to 3.6) <0.001 
eGFR 
(mls/min/1.73m2) 0.1(0.03 to 0.2) 0.006 0.02(-0.02 to 0.06) 0.4 
+thalassemia 
genotype 0.04(-1.4 to1.5) 1.0 0.1(-0.8 to 1.1) 0.8 
Likelihood ratio test for models including vs excluding +thalassemia genotype p= 1.0 for SBP 
and p=0.8 for DBP. 
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Figures 
Figure 1: Study flow chart 
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Figure 2: 24-hour ABPM measures by alpha thalassemia status 
Data are mean and 95% Confidence Intervals 
 
 
 
 
